Compare Abeona Therapeutics Inc (ABEO) vs Vertiv Holdings Co (VRT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Vertiv Holdings Co — how do they compare? Abeona Therapeutics Inc trades at $6.7 (market cap $373.32M), while Vertiv Holdings Co trades at $316 (market cap $117.38B). The key difference: Vertiv Holdings Co is far larger — about 314.4× Abeona Therapeutics Inc's market cap, and Vertiv Holdings Co pays a 0.08% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | VRT | |
|---|---|---|
Market Cap | $373.32M | $117.38B |
Sector | Health | Technology |
52-Week High | $7.23 | $376.23 |
52-Week Low | $4.17 | $120.72 |
Enterprise Value | $228.22M | $118.14B |
Dividend Yield | — | 0.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Vertiv Holdings (VRT) trades at $318.47, up 5.97% with strong bullish momentum. The stock shows robust fundamentals with Q1 2026 EPS beating estimates at $1.17 versus $1.00 expected, continuing a pattern of earnings outperformance. Technical indicators signal bullish momentum with the current price near pivot point resistance at $319. The company benefits from AI infrastructure demand, supported by recent manufacturing expansion in Malaysia and strategic acquisitions enhancing its data center portfolio.
Outlook remains positive with 94.7% analyst buy ratings and a $395.23 consensus price target implying 24% upside. Key risks include premium valuation multiples (P/E 80.02) and execution challenges in scaling operations. The AI infrastructure boom presents significant growth opportunity, though investors should monitor competitive pressures and macroeconomic conditions affecting data center spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Vertiv Holdings Co
Vertiv is a global leader in critical digital infrastructure, providing essential power, cooling, and IT management solutions for data centers, communication networks, and industrial facilities. As the primary provider of advanced thermal management and liquid cooling systems, Vertiv is a central player in the AI revolution, enabling the extreme density and power requirements of next-generation GPU-driven computing.
Read more on VRT →
